{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:56:18Z","timestamp":1790657778003,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03683-4","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T03:53:12Z","timestamp":1783569192000},"page":"4344-4354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Eight-Century Evolution of Asthma Therapeutics in Western Countries: From Medieval Regimens to Anti-inflammatory Reliever Therapy and Precision Biologics"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8553-9167","authenticated-orcid":false,"given":"Nestor A.","family":"Molfino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"4","key":"3683_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1136\/thx.36.4.245","volume":"36","author":"F Rosner","year":"1981","unstructured":"Rosner F. Moses Maimonides\u2019 treatise on asthma. Thorax. 1981;36(4):245\u201351. https:\/\/doi.org\/10.1136\/thx.36.4.245.","journal-title":"Thorax"},{"issue":"43","key":"3683_CR2","first-page":"187","volume":"22","author":"HH Salter","year":"1858","unstructured":"Salter HH. On the Pathology of Asthma. Edinb Med J. 1858;22(43):187\u2013208.","journal-title":"Edinb Med J"},{"issue":"1","key":"3683_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1089\/jamp.2016.1297","volume":"30","author":"SW Stein","year":"2017","unstructured":"Stein SW, Thiel CG. The history of therapeutic aerosols: a chronological review. J Aerosol Med Pulm Drug Deliv. 2017;30(1):20\u201341. https:\/\/doi.org\/10.1089\/jamp.2016.1297.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"6","key":"3683_CR4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.pcrj.2006.09.002","volume":"15","author":"G Crompton","year":"2006","unstructured":"Crompton G. A brief history of inhaled asthma therapy over the last fifty years. Prim Care Respir J. 2006;15(6):326\u201331. https:\/\/doi.org\/10.1016\/j.pcrj.2006.09.002.","journal-title":"Prim Care Respir J"},{"issue":"7615","key":"3683_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0140-6736(69)90051-8","volume":"2","author":"WHW Inman","year":"1969","unstructured":"Inman WHW, Adelstein AM. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet. 1969;2(7615):279\u201385. https:\/\/doi.org\/10.1016\/S0140-6736(69)90051-8.","journal-title":"Lancet"},{"issue":"8644","key":"3683_CR6","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(89)92505-1","volume":"1","author":"J Crane","year":"1989","unstructured":"Crane J, Pearce N, Flatt A, Burgess C, Jackson R, Kwong T, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981\u201383: case-control study. Lancet. 1989;1(8644):917\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(89)92505-1.","journal-title":"Lancet"},{"key":"3683_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000195.pub2","volume":"3","author":"BH Rowe","year":"2007","unstructured":"Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev. 2007;3:CD000195. https:\/\/doi.org\/10.1002\/14651858.CD000195.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"3683_CR8","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1056\/NEJM200008033430504","volume":"343","author":"S Suissa","year":"2000","unstructured":"Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343(5):332\u20136. https:\/\/doi.org\/10.1056\/NEJM200008033430504.","journal-title":"N Engl J Med"},{"issue":"10","key":"3683_CR9","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1136\/thorax.57.10.880","volume":"57","author":"S Suissa","year":"2002","unstructured":"Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax. 2002;57(10):880\u20134. https:\/\/doi.org\/10.1136\/thorax.57.10.880.","journal-title":"Thorax"},{"key":"3683_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001117","volume":"1","author":"PG Gibson","year":"2003","unstructured":"Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood P, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev. 2003;1:CD001117. https:\/\/doi.org\/10.1002\/14651858.CD001117.","journal-title":"Cochrane Database Syst Rev"},{"key":"3683_CR11","volume-title":"Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma","author":"National Asthma Education and Prevention Program","year":"2007","unstructured":"National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Heart, Lung, and Blood Institute; 2007."},{"issue":"6","key":"3683_CR12","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","volume":"146","author":"MM Cloutier","year":"2020","unstructured":"Cloutier MM, Baptist AP, Blake KV, Brooks EG, Bryant-Stephens T, DiMango E, et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020;146(6):1217\u201370. https:\/\/doi.org\/10.1016\/j.jaci.2020.10.003.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"3683_CR13","doi-asserted-by":"publisher","first-page":"1901046","DOI":"10.1183\/13993003.01046-2019","volume":"53","author":"HK Reddel","year":"2019","unstructured":"Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, et al. GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019;53(6):1901046. https:\/\/doi.org\/10.1183\/13993003.01046-2019.","journal-title":"Eur Respir J"},{"issue":"1","key":"3683_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41533-023-00330-1","volume":"33","author":"ML Levy","year":"2023","unstructured":"Levy ML, Bacharier LB, Bateman ED, Boulet LP, Brightling C, Buhl R, et al. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. NPJ Prim Care Respir Med. 2023;33(1):7. https:\/\/doi.org\/10.1038\/s41533-023-00330-1.","journal-title":"NPJ Prim Care Respir Med"},{"issue":"172","key":"3683_CR15","doi-asserted-by":"publisher","first-page":"230238","DOI":"10.1183\/16000617.0238-2023","volume":"33","author":"C Kyriakopoulos","year":"2024","unstructured":"Kyriakopoulos C, Gogali A, Markozannes G, Kostikas K. Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials. Eur Respir Rev. 2024;33(172):230238. https:\/\/doi.org\/10.1183\/16000617.0238-2023.","journal-title":"Eur Respir Rev"},{"issue":"5","key":"3683_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1056\/NEJM199101313240502","volume":"324","author":"NA Molfino","year":"1991","unstructured":"Molfino NA, Nannini LJ, Martelli AN, Slutsky AS. Respiratory arrest in near-fatal asthma. N Engl J Med. 1991;324(5):285\u20138. https:\/\/doi.org\/10.1056\/NEJM199101313240502.","journal-title":"N Engl J Med"},{"issue":"4","key":"3683_CR17","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1164\/ajrccm\/142.4.832","volume":"142","author":"EF Juniper","year":"1990","unstructured":"Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O\u2019Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis. 1990;142(4):832\u20136. https:\/\/doi.org\/10.1164\/ajrccm\/142.4.832.","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"3683_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/imr.70025","volume":"331","author":"JM Kornfield","year":"2025","unstructured":"Kornfield JM, Bright HATK, Drake MG. Touching a nerve: neuroimmune interactions in asthma. Immunol Rev. 2025;331(1):e70025. https:\/\/doi.org\/10.1111\/imr.70025.","journal-title":"Immunol Rev"},{"issue":"457","key":"3683_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar8477","volume":"10","author":"MG Drake","year":"2018","unstructured":"Drake MG, Scott GD, Blum ED, Lebold KM, Nie Z, Lee JJ, et al. Eosinophils increase airway sensory nerve density in mice and in human asthma. Sci Transl Med. 2018;10(457):eaar8477. https:\/\/doi.org\/10.1126\/scitranslmed.aar8477.","journal-title":"Sci Transl Med"},{"key":"3683_CR20","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta-agonists used in combination with inhaled corticosteroids. December 20, 2017. Accessed April 27, 2026. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-review-finds-no-significant-increase-risk-serious-asthma-outcomes"},{"issue":"1","key":"3683_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ajem.2014.09.036","volume":"33","author":"RM Nowak","year":"2015","unstructured":"Nowak RM, Parker JM, Silverman RA, Rowe BH, Smithline H, Khan F, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. Am J Emerg Med. 2015;33(1):14\u201320. https:\/\/doi.org\/10.1016\/j.ajem.2014.09.036.","journal-title":"Am J Emerg Med"},{"issue":"1","key":"3683_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S2213-2600(24)00299-6","volume":"13","author":"S Ramakrishnan","year":"2025","unstructured":"Ramakrishnan S, Russell REK, Mahmood HR, Krassowska K, Melhorn J, Mwasuku C, et al. Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial. Lancet Respir Med. 2025;13(1):59\u201368. https:\/\/doi.org\/10.1016\/S2213-2600(24)00299-6.","journal-title":"Lancet Respir Med"},{"key":"3683_CR23","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics. FastStats: Asthma. Last reviewed February 20, 2026. Accessed April 27, 2026. https:\/\/www.cdc.gov\/nchs\/fastats\/asthma.htm"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03683-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03683-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03683-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:16:13Z","timestamp":1790655373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03683-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3683"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03683-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nestor A. Molfino is an employee of Amgen Inc. Paul M. O'Byrne has obtained grants in aid of research from Novartis, AstraZeneca, Biohaven, Merck, and Jasper for research, and received personal fees for consulting or speaker fees from AstraZeneca, GSK, and Sonafi\/Regeneron.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}